A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

Lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

With

• The Affiliated Hospital Of Guizhou Medical University
• The First Hospital of Jilin University
• People's Hospital of Ningxia Hui Autonomous Region
• The First Affiliated Hospital of Dalian Medical University